UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia

Psychopharmacology, 2021-10, Vol.238 (10), p.2693-2708

2021

Volltextzugriff (PDF)

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

PloS one, 2012-10, Vol.7 (10), p.e47662-e47662

2012

Volltextzugriff (PDF)

Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension

Journal of medicinal chemistry, 2015-09, Vol.58 (18), p.7128-7137

2015

Volltextzugriff (PDF)

Mechanisms of ET-1-induced Endothelial Dysfunction

Journal of cardiovascular pharmacology, 2007-12, Vol.50 (6), p.621-628

2007

Volltextzugriff (PDF)

At the heart of tissue: endothelin system and end-organ damage

Clinical science (1979), 2010-12, Vol.119 (11), p.453-463

2010

Volltextzugriff (PDF)

The Discovery of N‑[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]‑N′‑propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist

Journal of medicinal chemistry, 2012-09, Vol.55 (17), p.7849-7861

2012

Volltextzugriff (PDF)

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

The Journal of pharmacology and experimental therapeutics, 2008-12, Vol.327 (3), p.736-745

2008

Volltextzugriff (PDF)

The Cardiovascular Physiology and Pharmacology of Endothelin-1

Advances in Pharmacology, 2010, Vol.60, p.1-26

2010

Volltextzugriff (PDF)

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation

The Journal of pharmacology and experimental therapeutics, 2011-05, Vol.337 (2), p.547-556

2011

Volltextzugriff (PDF)

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Nature medicine, 2007-02, Vol.13 (2), p.150-155

2007

Volltextzugriff (PDF)

Aprocitentan and the endothelin system in resistant hypertension

Canadian journal of physiology and pharmacology, 2022-07, Vol.100 (7), p.573-583

Clozel, Martine

2022

Volltextzugriff (PDF)

CRISPR‐Cas9‐modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine‐containing compounds but potentiates artemisinin‐based combination therapy partner drugs

Molecular microbiology, 2016-08, Vol.101 (3), p.381-393

2016

Volltextzugriff (PDF)

Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery

The Journal of pharmacology and experimental therapeutics, 2012-12, Vol.343 (3), p.547-555

2012

Volltextzugriff (PDF)

Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension

American journal of physiology. Regulatory, integrative and comparative physiology, 2016-10, Vol.311 (4), p.R721-R726

Clozel, Martine

2016

Volltextzugriff (PDF)

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension

Life sciences (1973), 2014-11, Vol.118 (2), p.333-339

2014

Volltextzugriff (PDF)

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling

PLoS medicine, 2016-10, Vol.13 (10), p.e1002138

2016

Volltextzugriff (PDF)

Development of macitentan for the treatment of pulmonary arterial hypertension

Annals of the New York Academy of Sciences, 2015-11, Vol.1358 (1), p.68-81

2015

Volltextzugriff (PDF)

Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator

PloS one, 2013-09, Vol.8 (9), p.e74285

2013

Volltextzugriff (PDF)

Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes

PloS one, 2013-10, Vol.8 (10), p.e77296-e77296

2013

Volltextzugriff (PDF)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension

Journal of cardiovascular pharmacology, 2015-11, Vol.66 (5), p.457-467

2015

Volltextzugriff (PDF)

The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats

The Journal of pharmacology and experimental therapeutics, 2006-03, Vol.316 (3), p.1115-1121

2006

Volltextzugriff (PDF)

Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat

The Journal of pharmacology and experimental therapeutics, 2004-03, Vol.308 (3), p.1121-1129

2004

Volltextzugriff (PDF)

Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System

The Journal of pharmacology and experimental therapeutics, 2004-10, Vol.311 (1), p.204-212

2004

Volltextzugriff (PDF)

Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use

The Journal of pharmacology and experimental therapeutics, 1999-08, Vol.290 (2), p.840

1999

Volltextzugriff (PDF)

Between confidentiality and scientific exchange: the place of publication in drug discovery and pharmaceutical research

Science translational medicine, 2011-01, Vol.3 (67), p.67cm2

Clozel, Martine

2011

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(132)

Publikationsform

Artikel
(158)
Buchkapitel
(1)

Sprache

Englisch
(159)
Japanisch
(48)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension

Mechanisms of ET-1-induced Endothelial Dysfunction

At the heart of tissue: endothelin system and end-organ damage

The Discovery of N‑[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]‑N′‑propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

The Cardiovascular Physiology and Pharmacology of Endothelin-1

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation

Promotion of sleep by targeting the orexin system in rats, dogs and humans

Aprocitentan and the endothelin system in resistant hypertension

CRISPR‐Cas9‐modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine‐containing compounds but potentiates artemisinin‐based combination therapy partner drugs

Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery

Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling

Development of macitentan for the treatment of pulmonary arterial hypertension

Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator

Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension

The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats

Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat

Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System

Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use

Between confidentiality and scientific exchange: the place of publication in drug discovery and pharmaceutical research

Suchergebnisse filtern